PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
53.82%
Cash & equivalents yoy growth 0.5-0.75x CRVO's 82.09%. Martin Whitman would worry if slower accumulation signals weaker operations or bigger outflows.
No Data
No Data available this quarter, please select a different quarter.
53.82%
Cash + STI yoy 0.5-0.75x CRVO's 82.09%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
54.98%
0.5-0.75x CRVO's 76.80%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-8.67%
1.25-1.5x CRVO's -6.08%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.00%
0.75-0.9x CRVO's -1.23%. Bill Ackman questions if the competitor invests more robustly in future growth.
No Data
No Data available this quarter, please select a different quarter.
53.46%
≥ 1.5x CRVO's 27.62%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
21.21%
Less than half of CRVO's -18.14%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-57.02%
Less than half of CRVO's 191.21%. David Dodd sees fewer expansions in other current obligations.
37.02%
Less than half of CRVO's -47.12%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.02%
Less than half of CRVO's -25.82%. David Dodd sees far fewer liability expansions relative to competitor.
37.77%
Less than half of CRVO's 5119.63%. David Dodd sees fewer share issuances vs. competitor.
-3.87%
0.5-0.75x CRVO's -5.38%. Martin Whitman is wary of weaker retention or lower profitability.
-5.55%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
59.08%
1.25-1.5x CRVO's 39.99%. Bruce Berkowitz notes an above-average equity expansion.
53.46%
≥ 1.5x CRVO's 27.62%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.82%
50-75% of CRVO's -87.50%. Bruce Berkowitz notes comparatively lower net debt expansion.